Immunosuppression in elderly renal transplant recipients: Are current regimens too aggressive?

Herwig Ulf Meier-Kriesche, Bruce Kaplan

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Renal transplantation is an accepted and successful treatment modality in elderly patients with end-stage renal disease. In comparison with maintenance dialysis, transplantation has been shown to confer a mortality benefit as well as improvements in quality of life in older individuals with end-stage renal disease. Despite this, overall outcomes of renal transplantation in elderly individuals have, in general, been less successful than those of younger renal transplant recipients. Largely, this has been due to the particular vulnerability of elderly patients to the immunosuppressive medications used in renal transplantation. This review article covers these issues in some detail and briefly discusses some of the pharmacokinetic, pharmacodynamic, physiological and immunological differences between younger and older transplant recipients. Elderly renal transplant recipients have both a higher rate of patient death and allograft loss censored for death. Upon multivariate analysis, age of the recipient is strongly associated with allograft loss independent of other known factors. Acute rejections are less frequent in older individuals; however the consequence of a rejection if it occurs is negative for long-term graft survival. On the other hand, death by infection is vastly increased in older versus younger renal transplant recipients. In general, the pharmacokinetics of the immunosuppressive agents are little affected by age, but the tolerance to these agents seems to decrease with increasing age. Elderly renal transplant recipients present a very difficult clinical challenge. As the elderly become an ever-increasing segment of the renal transplant population, new and innovative immunosuppressive strategies will have to be considered and applied.

Original languageEnglish (US)
Pages (from-to)751-759
Number of pages9
JournalDrugs and Aging
Volume18
Issue number10
StatePublished - 2001
Externally publishedYes

Fingerprint

Immunosuppression
Kidney
Immunosuppressive Agents
Kidney Transplantation
Chronic Kidney Failure
Allografts
Pharmacokinetics
Mortality
Graft Survival
Transplant Recipients
Dialysis
Multivariate Analysis
Transplantation
Maintenance
Quality of Life
Transplants
Infection
Population

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Immunosuppression in elderly renal transplant recipients : Are current regimens too aggressive? / Meier-Kriesche, Herwig Ulf; Kaplan, Bruce.

In: Drugs and Aging, Vol. 18, No. 10, 2001, p. 751-759.

Research output: Contribution to journalArticle

Meier-Kriesche, Herwig Ulf ; Kaplan, Bruce. / Immunosuppression in elderly renal transplant recipients : Are current regimens too aggressive?. In: Drugs and Aging. 2001 ; Vol. 18, No. 10. pp. 751-759.
@article{6108dfc704df4f0c920f7d036f1d4d15,
title = "Immunosuppression in elderly renal transplant recipients: Are current regimens too aggressive?",
abstract = "Renal transplantation is an accepted and successful treatment modality in elderly patients with end-stage renal disease. In comparison with maintenance dialysis, transplantation has been shown to confer a mortality benefit as well as improvements in quality of life in older individuals with end-stage renal disease. Despite this, overall outcomes of renal transplantation in elderly individuals have, in general, been less successful than those of younger renal transplant recipients. Largely, this has been due to the particular vulnerability of elderly patients to the immunosuppressive medications used in renal transplantation. This review article covers these issues in some detail and briefly discusses some of the pharmacokinetic, pharmacodynamic, physiological and immunological differences between younger and older transplant recipients. Elderly renal transplant recipients have both a higher rate of patient death and allograft loss censored for death. Upon multivariate analysis, age of the recipient is strongly associated with allograft loss independent of other known factors. Acute rejections are less frequent in older individuals; however the consequence of a rejection if it occurs is negative for long-term graft survival. On the other hand, death by infection is vastly increased in older versus younger renal transplant recipients. In general, the pharmacokinetics of the immunosuppressive agents are little affected by age, but the tolerance to these agents seems to decrease with increasing age. Elderly renal transplant recipients present a very difficult clinical challenge. As the elderly become an ever-increasing segment of the renal transplant population, new and innovative immunosuppressive strategies will have to be considered and applied.",
author = "Meier-Kriesche, {Herwig Ulf} and Bruce Kaplan",
year = "2001",
language = "English (US)",
volume = "18",
pages = "751--759",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Immunosuppression in elderly renal transplant recipients

T2 - Are current regimens too aggressive?

AU - Meier-Kriesche, Herwig Ulf

AU - Kaplan, Bruce

PY - 2001

Y1 - 2001

N2 - Renal transplantation is an accepted and successful treatment modality in elderly patients with end-stage renal disease. In comparison with maintenance dialysis, transplantation has been shown to confer a mortality benefit as well as improvements in quality of life in older individuals with end-stage renal disease. Despite this, overall outcomes of renal transplantation in elderly individuals have, in general, been less successful than those of younger renal transplant recipients. Largely, this has been due to the particular vulnerability of elderly patients to the immunosuppressive medications used in renal transplantation. This review article covers these issues in some detail and briefly discusses some of the pharmacokinetic, pharmacodynamic, physiological and immunological differences between younger and older transplant recipients. Elderly renal transplant recipients have both a higher rate of patient death and allograft loss censored for death. Upon multivariate analysis, age of the recipient is strongly associated with allograft loss independent of other known factors. Acute rejections are less frequent in older individuals; however the consequence of a rejection if it occurs is negative for long-term graft survival. On the other hand, death by infection is vastly increased in older versus younger renal transplant recipients. In general, the pharmacokinetics of the immunosuppressive agents are little affected by age, but the tolerance to these agents seems to decrease with increasing age. Elderly renal transplant recipients present a very difficult clinical challenge. As the elderly become an ever-increasing segment of the renal transplant population, new and innovative immunosuppressive strategies will have to be considered and applied.

AB - Renal transplantation is an accepted and successful treatment modality in elderly patients with end-stage renal disease. In comparison with maintenance dialysis, transplantation has been shown to confer a mortality benefit as well as improvements in quality of life in older individuals with end-stage renal disease. Despite this, overall outcomes of renal transplantation in elderly individuals have, in general, been less successful than those of younger renal transplant recipients. Largely, this has been due to the particular vulnerability of elderly patients to the immunosuppressive medications used in renal transplantation. This review article covers these issues in some detail and briefly discusses some of the pharmacokinetic, pharmacodynamic, physiological and immunological differences between younger and older transplant recipients. Elderly renal transplant recipients have both a higher rate of patient death and allograft loss censored for death. Upon multivariate analysis, age of the recipient is strongly associated with allograft loss independent of other known factors. Acute rejections are less frequent in older individuals; however the consequence of a rejection if it occurs is negative for long-term graft survival. On the other hand, death by infection is vastly increased in older versus younger renal transplant recipients. In general, the pharmacokinetics of the immunosuppressive agents are little affected by age, but the tolerance to these agents seems to decrease with increasing age. Elderly renal transplant recipients present a very difficult clinical challenge. As the elderly become an ever-increasing segment of the renal transplant population, new and innovative immunosuppressive strategies will have to be considered and applied.

UR - http://www.scopus.com/inward/record.url?scp=0035214978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035214978&partnerID=8YFLogxK

M3 - Article

C2 - 11735622

AN - SCOPUS:0035214978

VL - 18

SP - 751

EP - 759

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 10

ER -